Diabetic Retinopathy Medical Services in China

Diabetic retinopathy (DR) is a progressive microvascular complication of diabetes mellitus and the leading cause of preventable blindness among working-age adults worldwide. It results from chronic hyperglycemia-induced damage to the retinal capillaries, leading to vascular leakage, ischemia, inflammation, and pathological neovascularization. Pathogenesis involves multiple interrelated mechanisms: persistent hyperglycemia triggers oxidative stress, advanced glycation end-product (AGE) accumulation, protein kinase C activation, and polyol pathway flux — all contributing to pericyte loss, basement membrane thickening, endothelial dysfunction, and breakdown of the blood-retinal barrier. As disease advances, non-proliferative diabetic retinopathy (NPDR) may evolve into proliferative diabetic retinopathy (PDR), characterized by fragile new vessels prone to vitreous hemorrhage and tractional retinal detachment. Epidemiologically, approximately one-third of people with diabetes have some form of DR, with prevalence rising to over 50% in those with >20 years’ duration of type 1 or type 2 diabetes. Globally, an estimated 93 million people live with DR, and nearly 3 million suffer vision-threatening stages. Key modifiable risk factors include poor glycemic control (elevated HbA1c), hypertension, dyslipidemia, duration of diabetes, pregnancy, and renal disease; non-modifiable factors include genetic susceptibility, ethnicity (higher incidence in Hispanic and African American populations), and age. Early-stage DR is typically asymptomatic, delaying diagnosis until irreversible structural damage occurs. As it progresses, patients may experience blurred or fluctuating vision, floaters, dark or empty areas in the visual field, impaired color perception, and sudden vision loss. Beyond functional impairment, DR significantly diminishes quality of life—contributing to anxiety, depression, reduced mobility, occupational limitations, social isolation, and increased caregiver burden. Timely screening via dilated fundus examination or ultra-widefield retinal imaging is critical, as early intervention can reduce severe vision loss by up to 95%. Multidisciplinary management involving endocrinologists, ophthalmologists, and primary care providers is essential for optimizing systemic control and ocular outcomes.

Diabetic retinopathy (DR) is a microvascular complication of diabetes mellitus characterized by progressive damage to the retinal vasculature, leading to vision impairment and potential blindness if untreated. As an endocrinology-driven condition, its management requires tight glycemic, blood pressure, and lipid control alongside ophthalmologic surveillance and intervention. Treatment strategies are stratified by disease severity—ranging from mild non-proliferative DR (NPDR) to severe NPDR and proliferative DR (PDR)—and must be individualized based on systemic comorbidities, duration of diabetes, and ocular findings.

Conservative treatment forms the cornerstone of early and intermediate DR management. This includes rigorous metabolic optimization: hemoglobin A1c targets should generally be maintained at <7.0% (53 mmol/mol) for most adults, with individualized goals for elderly or frail patients to avoid hypoglycemia. Blood pressure control to <130/80 mmHg is strongly recommended, with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) preferred in patients with diabetic kidney disease due to their renoprotective and potential retinoprotective effects. Lipid management—particularly lowering LDL cholesterol to <2.6 mmol/L (<100 mg/dL), or <1.8 mmol/L (<70 mg/dL) in high-risk individuals—is supported by evidence showing reduced progression of retinal hard exudates and macular edema. Lifestyle interventions—including medical nutrition therapy, structured physical activity (≥150 min/week moderate-intensity aerobic exercise), smoking cessation, and weight management—are integral to sustaining metabolic control and reducing oxidative stress and inflammation implicated in retinal endothelial injury.

Pharmacotherapy for DR remains largely adjunctive, as no systemic drug is currently FDA- or EMA-approved specifically to halt or reverse retinopathy progression. However, intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents—including ranibizumab, aflibercept, and faricimab—are first-line for center-involving diabetic macular edema (DME) and are increasingly used in PDR. These agents inhibit VEGF-mediated vascular permeability and neovascularization, significantly improving visual acuity and reducing retinal thickness. Intravitreal corticosteroids (e.g., dexamethasone implant, fluocinolone acetonide implant) serve as alternatives in pseudophakic eyes or cases refractory to anti-VEGF therapy, though they carry higher risks of cataract progression and intraocular pressure elevation. Systemically, fenofibrate—a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist—has demonstrated modest but statistically significant reduction in DR progression in the FIELD and ACCORD Eye studies, independent of lipid-lowering effects, likely via anti-inflammatory and antioxidant mechanisms. Metformin may confer indirect benefit through improved insulin sensitivity and reduced systemic inflammation, while SGLT2 inhibitors and GLP-1 receptor agonists show emerging promise in reducing microvascular complications, although direct retinopathy-specific outcome data remain limited.

Surgical treatment is indicated when conservative and pharmacologic measures fail or when sight-threatening complications arise. Focal/grid laser photocoagulation was historically standard for DME but has been largely superseded by anti-VEGF therapy due to superior visual outcomes and lower risk of peripheral vision loss or macular atrophy. Panretinal photocoagulation (PRP) remains a mainstay for high-risk PDR, inducing regression of neovascularization by ablating ischemic retina and reducing VEGF drive; however, it carries risks of night vision deficits, peripheral field constriction, and macular edema exacerbation. Vitrectomy is performed for advanced complications including non-clearing vitreous hemorrhage, tractional retinal detachment involving the macula, or combined traction-rhegmatogenous retinal detachment. Modern 25- or 27-gauge transconjunctival sutureless vitrectomy systems enable faster recovery, reduced postoperative inflammation, and earlier visual rehabilitation. In select cases, adjunctive intraoperative anti-VEGF injection during vitrectomy improves surgical visualization and reduces postoperative neovascular recurrence.

China offers distinct advantages in DR management, particularly in integrated care delivery and technological adoption. The national 'Healthy China 2030' initiative prioritizes diabetic eye screening, enabling widespread deployment of AI-assisted retinal imaging platforms—such as DeepMind-derived algorithms validated in Chinese populations—that allow primary care physicians and community health workers to perform reliable, real-time DR grading using portable fundus cameras. Over 300 tertiary hospitals now operate multidisciplinary Diabetes-Retina Clinics co-staffed by endocrinologists and vitreoretinal specialists, facilitating same-day metabolic assessment and ophthalmic evaluation. China’s robust generic pharmaceutical industry ensures broad access to biosimilar anti-VEGF agents (e.g., conbercept, a recombinant fusion protein approved by NMPA in 2013) at approximately 30–40% lower cost than originators, enhancing treatment adherence. Additionally, China leads globally in tele-ophthalmology infrastructure, with over 90% coverage of county-level hospitals linked to provincial referral centers via secure cloud-based image transmission and decision-support systems. Clinical trial participation is also high, with Chinese sites contributing substantially to pivotal phase III trials of next-generation therapies including gene-delivered anti-VEGF (e.g., RGX-314) and sustained-release implants.

Recovery and long-term prognosis depend heavily on patient engagement and continuity of care. Post-treatment, patients must maintain strict glycemic targets and attend scheduled ophthalmologic follow-up—every 3–6 months for stable NPDR, monthly during active DME treatment, and quarterly after PRP or vitrectomy. Patients receiving intravitreal injections should monitor for signs of endophthalmitis (acute pain, worsening vision, photophobia, hypopyon) and report them immediately. Visual rehabilitation may include low-vision aids (magnifiers, electronic readers) and orientation/mobility training for those with irreversible vision loss. Psychosocial support is critical: depression and diabetes distress are prevalent in DR patients and correlate with poor self-management; integration of mental health screening into routine endocrine visits is increasingly standard in major Chinese centers. Finally, annual comprehensive dilated eye exams remain non-negotiable—even in patients with well-controlled diabetes—as DR can progress asymptomatically until advanced stages. Empowerment through diabetes self-management education (DSME), including foot and eye care modules delivered in Mandarin and regional dialects, significantly improves screening adherence and reduces preventable blindness rates across urban and rural settings.